News | August 02, 2007

Medipattern Announces Closing of $5.2 Million Financing Deal

August 3, 2007 - Medipattern Corp., a developer of computer-aided diagnosis (CAD) medical imaging software designed to detect cancer announced it has closed a deal with Research Capital Corp. issuing 4,730,000 common shares at a price of $1.10 per share for aggregate gross proceeds of $5,203,000.

Research Capital Corp. has an option, exercisable for a period of 30 days following the closing date, to purchase from the Company up to an additional 15 percent, or 709,500 common shares, for further gross proceeds of $780,450 to cover over-allotments and for market stabilization purposes. Research Capital Corporation also received a Compensation Option, exercisable for a period of 24 months following the closing date, to purchase up to an additional 283,800 common shares at $1.10 per share.

The Company intends to use the net proceeds of the offering for: commercialization of B-CAD-MRITM, for breast MR imaging; continued development of product extensions for B-CADTM for breast ultrasound imaging; filing a Pre Market Approval (PMA) with the Food and Drug Administration of the United States for the B-CAD technology; expanding Sales and Marketing initiatives, and general operating purposes.

For more information: www.medipattern.com

Related Content

MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
Technology | Artificial Intelligence | November 07, 2018
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance...
iCAD Announces Positive Clinical Results for Artificial Intelligence Tomosynthesis Technology
News | Mammography | October 11, 2018
iCAD Inc. announced positive clinical results of its new digital breast tomosynthesis (DBT) cancer detection software,...
SimonMed Deploys ClearRead CT Enterprise Wide
News | Computer-Aided Detection Software | September 17, 2018
September 17, 2018 — National outpatient physician radiology group SimonMed Imaging has selected Riverain Technologie
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Riverain Technologies Issued U.S. Patent for Vessel Suppression Technology
News | Computed Tomography (CT) | June 14, 2018
Riverain Technologies announced that the United States Patent and Trademark Office (USPTO) has awarded the company a...
FDA Issues Proposed Order to Reclassify Certain Radiological Medical Image Analyzers
News | Computer-Aided Detection Software | June 01, 2018
The U.S. Food and Drug Administration (FDA) is issuing a proposed order to reclassify certain radiological medical...
Median Technologies and the Nice University Hospital to Use AI in Lung Cancer Screening
News | Artificial Intelligence | March 15, 2018
March 15, 2018 – Median Technologies, the industry-leading Imaging Phenomics Company and the Nice University Hospital
FDA Clears First AI-Powered Clinical Decision Support Software for Stroke
Technology | Clinical Decision Support | February 14, 2018
The U.S. Food and Drug Administration (FDA) announced marketing clearance for Viz.AI’s Contact application, the first ...
Transpara Deep Learning Software Matches Experienced Radiologists in Mammogram Reading
News | Computer-Aided Detection Software | January 12, 2018
Deep learning and artificial intelligence improves the efficiency and accuracy of reading mammograms, according to...